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Aim To investigate the therapeutic and immunoregulatory 
effects of 1,25-dihydroxyvitamin D (1,25(OH)D3) on 2,4,6-
trinitrobenzenesulfonic acid (TNBS) -induced colitis in rats.
Methods Experimental colitis induced by enema adminis-
tration of TNBS plus ethanol was treated with 5-aminosal-
icylic acid (5-ASA) and/or 1,25(OH)D3. Disease activity was 
measured using the disease activation index (DAI), colon 
macroscopic damage index (CMDI), histological colonic 
damage score, and myeloperoxidase (MPO) activity. The 
expression of toll-like receptor 9 (TLR9) in the colon was 
determined by reverse transcription-polymerase chain re-
action and immunohistochemistry.
Results Rats with TNBS-induced colitis had significantly el-
evated DAI, CMDI, histological colonic damage score, and 
MPO activity (all P < 0.001) compared to rats without coli-
tis. Treatment with 5-ASA or 1,25(OH)D3 ameliorated colitis 
by lowering CMDI (P = 0.049, P = 0.040, respectively), histo-
logical colonic damage score (P = 0.010, P = 0.005, respec-
tively), and MPO activity (P = 0.0003, P = 0.0013, respective-
ly) compared with the TNBS group. Combined treatment 
with 5-ASA and 1,25(OH)D3 significantly decreased MPO 
activity (P = 0.003). 1,25(OH)D3 attenuated colitis without 
causing hypercalcemia or renal insufficiency. TNBS signif-
icantly increased the number of TLR9 positive cells com-
pared to control (P < 0.010), while 5-ASA, 1,25(OH)D3, and 
combined treatment with 5-ASA and 1,25(OH)D3 signifi-
cantly decreased it compared to TNBS group (all P < 0.010). 
In TNBS group a moderate correlation was observed be-
tween MPO activity and the number of TLR9-positive cells 
(r = 0.654, P < 0.001).
Conclusion TLR9 expression correlates with the extent of 
inflammation in TNBS-induced colitis. 1,25(OH)D3 relieves 
this inflammation possibly by decreasing TLR9 expression.
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Vitamin D is a well-known endocrine regulator of calci-
um homeostasis and 1,25-dihydroxyvitamin D (1,25(OH)
D3) is its biologically active form. Recent studies suggest 
that vitamin D deficiency is associated with the onset or 
increased activity of autoimmune diseases, especially Th1-
mediated autoimmune diseases, such as rheumatoid ar-
thritis, systemic lupus erythematosus, diabetes, multiple 
sclerosis, and inflammatory bowel disease (IBD) (1-3). Fur-
thermore, in Chinese patients with IBD, vitamin D deficien-
cy was observed to be partially related to higher risk of 
osteoporosis and increased disease activity (4). Therefore, 
vitamin D deficiency is considered an environment risk fac-
tor of IBD. Some researchers have proposed that vitamin D 
can modulate intestinal microflora, inhibit the adhesion of 
intestinal bacteria (5), protect the intestinal mucosal barrier 
(6,7), and reduce excessive external antigens presentation 
by antigen presenting cells (APCs) (8,9).
The most important antigen recognition receptors on APCs 
are toll-like receptors (TLRs). The TLRs signaling pathway is 
thought to play a key role in both innate immunity and 
adaptive immunity (10). TLRs recognize diverse ligands, in-
cluding lipids, lipoproteins, proteins, and nucleic acids de-
rived from microbes. TLR9 recognizes unmethylated cyto-
sine-phosphate-guanine (CpG) DNA motifs in bacteria and 
DNA viruses (11) and is essential for maturation of dendritic 
cells and release of pro-inflammatory cytokines. Increase in 
the expression of TLR9 was related to exposure of colonic 
epithelial cells to pathogenic bacterial DNA (12). Some re-
ports suggested that the excessive inflammatory response 
associated with a TLR9 polymorphism correlated with an 
increased risk of Crohn’s disease (CD) (13,14).
Previous studies have increased our understanding of the 
crosstalk between vitamin D and TLRs. Dickie et al (15) 
demonstrated that 1,25(OH)D3 down-regulated intracel-
lular TLR9 expression and TLR9-induced IL-6 production 
in healthy human monocytes in vitro. It was also shown 
that by down-regulating the expressions of TLRs and pro-
inflammatory cytokines it improved herpes simplex vi-
rus-induced Behcet’s disease-like symptoms in mice (16). 
On the other hand, Edfeldt et al (17) found that TLRs en-
hanced bioconversion of 25-hydroxyvitamin D3 to its ac-
tive metabolite, 1,25(OH)D3, by inducting 25-hydroxyvita-
min D-1α-hydroxylase. Although previous studies showed 
that vitamin D could modulate intestinal microflora and 
TLR9 expression, the effect of vitamin D on IBD and its 
relationship with TLR9 expression in vivo still remained 
unclear. Therefore, the aim of this study was to inves-
tigate the effect of 1,25(OH)D3 on 2,4,6-trinitroben-
zenesulfonic acid (TNBS)-induced colitis and TLR9 expres-
sion in rats.
MaTeriaLs anD MeTHODs
rats experiments and induction of colitis by TnBs
Male, 8-10 week old Sprague-Dawley rats, weighing ap-
proximately 220 g, were obtained from Animal Science 
Department of Peking University Health Science Center 
(Beijing, China). All studies were approved by the Ethics 
Committee of Peking Union Medical College and were in 
agreement with the Beijing laboratory animal manage-
ment guidelines.
TNBS (100 mg/kg, Sigma-Aldrich, Shanghai, China) and 
50% ethanol were administered to anesthetized rats 
through a 2 mm polyethylene tube, which was carefully 
inserted into the rat’s rectum. To ensure uniform distribu-
tion of TNBS throughout the entire colon, rats were held 
in a vertical position for 5 min after the instillation of the 
TNBS enema.
1,25(OH)D3 (10 μg, Sigma-Aldrich) was dissolved in 4 mL 
ethanol and diluted with olive oil to obtain the concentra-
tion of 0.1 μg/mL. 1,25(OH)D3 and 5-ASA (Dr Falk Pharma 
GmbH, Freiburg, Germany) was administered by gavage. 
Thirty rats were randomly divided into five groups. One 
group was treated with ethanol only and served as con-
trol group. One group was treated with TNBS only. Vita-
min D treatment rats received 0.2 μg/kg/d 1,25(OH)D3. 
5-ASA treatment rats received 0.4 g/kg/d 5-ASA. Com-
bined 1,25(OH)D3 and 5-ASA treatment rats received 0.2 
μg/kg/d 1,25(OH)D3 and 0.4g/kg/d 5-ASA. These treat-
ments were initiated one day after the instillation of the 
TNBS enema and continued for 9 days. On the day 10, the 
rats were sacrificed and their colons removed. To monitor 
the adverse reaction of 1,25(OH)D3, serum calcium levels 
and serum creatinine levels were determined at the end 
of the experiment.
assessment of inflammatory activity
Disease Activation Index (DAI). DAI was used to assess the 
clinical severity of colitis according to Murano et al (18). 
The calculation was based on the daily body weight, stool 
consistency, and rectal bleeding. The loss of body weight 
was scored as follows: 0, no weight loss; 1, weight loss of 
0 to 5%; 2, weight loss of 5 to 10%; 3, weight loss of 10 
to 20%; and 4, weight loss >20%. Stool consistency was 
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scored as follows: 0, normally formed pellets; 2, pasty and 
semiformed pellets; and 4, liquid stool. Rectal bleeding was 
scored as follows: 0, no blood from the rectum and 4, gross 
bleeding from the rectum. These scores were summed, re-
sulting in a total clinical score ranging from 0 to 12.
Colon Macroscopic Damage Index (CMDI). The assessment 
of the CMDI was based on the area of inflammation and 
the presence of ulcers, according to Wallace and Keenan 
(19). Features were graded as follows: 0, no ulcer, no inflam-
mation; 1, no ulcer, local hyperemia; 2, ulceration without 
hyperemia; 3, ulceration and inflammation at one site only; 
4, two or more sites of ulceration and inflammation; 5, ul-
ceration extending more than 1 cm; 6, ulceration extend-
ing more than 2 cm.
Histological colonic damage. For histological examination, 
a sample of colonic tissue located 4-5 cm above the anal 
margin was obtained from rats in all treatment groups. 
The sections were stained with hematoxylin and eosin us-
ing routine techniques. Histological colonic damage was 
scored according to Sykes criteria (20). Features were grad-
ed from 0 to 5 in a blinded fashion, as follows: 0, no sig-
nificant damage; 1, damage confined to the epithelium; 
2, focal ulcers, limited to the mucosa; 3, focal transmural 
inflammation and ulceration; 4, extensive transmural in-
flammation and ulceration with normal mucosa around; 5, 
extensive transmural inflammation and ulceration with no 
normal mucosa.
Measurement of myeloperoxidase (MPO) activity. The se-
verity of acute colitis was measured by infiltration of neu-
trophils determined by photometrical assay for the neu-
trophil-specific MPO enzyme. The MPO activity assay was 
performed using an MPO kit (Jiancheng Bioengineering 
Institute, Nanjing, China) according to the method de-
scribed by Bradley et al (21). The enzyme activity was de-
termined photometrically. The MPO-catalyzed redox reac-
tion of 3,3’-dimethoxybenzidine changed the absorbance 
at 460 nm. The values were expressed as MPO units per 
gram of wet tissue.
reverse transcription-polymerase chain reaction (rT-
PCr) of TLr9 mitochondrial rna (mrna)
The expression of the TLR9 gene at the mRNA level in sam-
ples of rats’ colons was measured by RT-PCR. This meth-
od enables detection and semi-quantification of gene 
expression. RNA was extracted from samples of colon-
ic tissue located 5-6 cm above the anal margin using an 
RNAprep pure Tissue Kit (Tiangen Biotech, Beijing, China). 
RNA (2 μg) was used as a template in a cDNA synthesis re-
action performed in a Quant cDNA kit (Tiangen Biotech, 
Beijing, China). Housekeeping gene β-actin was amplified 
as reference gene for mRNA quantification. The primers 
for TLR9 were forward 5’- TCAACAAGAACACGCTCAGG-3’ 
and reverse 5’-GAGAGCTGGGGTGAGACTTG-3’ and β-actin 
forward 5’ -TCCTGTGGCATCCATGAAACT-3’ and reverse 
5’-GAAGCATTTGCGGTGCACGAT-3’. The primers were syn-
thesized by SinoGenoMax (Beijing, China). Amplifications 
were carried out in an Eppendorf gradient thermal cycler 
(Eppendorf, Hamburg, Germany). PCR cycling consisted of 
initial denaturation at 94°C for 3 min, followed by 35 cy-
cles at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, and 
then maintained at 72°C for 5 min. 10 μL of the PCR reac-
tion was run on precast 2.5% agarose Tris/Boric Acid/EDTA 
gels at 120 V. The level of TLR9 transcripts was calculated 
by relative quantification (22). The RT-PCR results were ex-
pressed as the level of TLR9 transcripts relative to the level 
of β-actin transcripts in the same samples using Quantity 
One 4.61 (Bio-Rad, Hercules, CA, USA).
immunohistochemistry (iHC) of TLr9 protein
IHC was performed using a specific primary mouse mono-
clonal antibody (Abcam, ab12121, Cambridge, UK) against 
TLR9 in a final 1:50 dilution. First, deparaffinized sections 
were heated in citrate buffer (pH 6.0) to induce epitope re-
trieval. After slow cooling to room temperature, the slides 
were incubated in 10% hydrogen peroxide and goat serum 
to block unwanted epitopes. The slides were then washed 
in phosphate-buffered saline (PBS) twice for 5 min and in-
cubated overnight at 4°C with primary antibody. Following 
this, they were stained with a chromogen purchased from 
ZSGB-BIO (PV-9000) (Beijing, China), washed in PBS, and 
counterstained with hematoxylin. The specimens were 
processed in the absence of primary antibody as negative 
controls. Positive staining was defined microscopically by 
visual identification of brown pigmentation either in the 
cytoplasm or nucleus. The TLR9 positive cells were count-
ed in 10 high power fields of each lesion by light micros-
copy at ×400 magnification. The number of TLR9 positive 
cells in each lesion was determined as the average number 
in 10 high power fields.
statistical analysis
Statistical analysis was performed using GraphPad Prism 5 
statistical software (GraphPad Software, Los Angeles, CA, 
USA). Normality of distribution was tested using Sha-
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piro-Wilk test and the data are expressed as mean ± standard 
deviation (SD). The differences between groups were tested 
using one-way analysis of variance and least-significant dif-
ference test. Correlation analysis was performed by bivariate 
correlation. Pearson correlation coefficient (r)>0.95 indicat-
ed significant correlation; r ≥0.8 high correlation; 0.5≤r <0.8 
moderate correlation; 0.3≤r <0.5 low correlation; r <0.3 no 
correlation; -1≤r <0 negative correlation. Differences were 
considered statistically significant at P < 0.050.
resuLTs
TnBs induced acute colitis in rats
Rats treated with TNBS developed acute colitis, character-
ized by weight loss, diarrhea, and rectal bleeding, especial-
ly in the first three days. Their body weight increased from 
the day 4 (Figure 1A). On the day 10, the control group had 
significantly greater weight than other groups (all P < 0.001); 
while there was no difference between TNBS-treated groups 
(P = 0.937, P = 0.571, P = 0.941) (Figure 1A). TNBS-treated rats 
had significantly higher DAI, CMDI, pathological score, and 
MPO values than control rats (all P < 0.001) (Figure 1B-E). 
In gross specimens, TNBS colitis is characterized by severe 
hyperemia and focal mucosal necrosis. In the TNBS coli-
tis groups, transmural inflammation was observed, char-
acterized by infiltration of inflammatory cells in the lamina 
propria. Some HE sections of TNBS-treated colitis groups 
showed ulcerations, loss of goblet cells, and diffuse fibrosis. 
Focal granulomas were also observed (Figure 2B-E).
5-asa and 1,25(OH)D3 attenuate TnBs colitis
We then treated TNBS-induced colitis rats with 5-ASA, 
1,25(OH)D3 and their combination. 5-ASA-treated rats 
showed significantly decreased CDMI (P = 0.049), patho-
Figure 1. analysis of colitis severity in rats under different treatments. (A) Weight gain. (B) Disease activation index score. (C) Colon 
macroscopic damage index. (D) Pathological score. (E) Myeloperoxidase activity. TnBs, 2,4,6-trinitrobenzenesulfonic acid; 5-asa, 
5-aminosalicylic acid; VitD3, 1,25-dihydroxyvitamin D. Data are presented as mean ± standard deviation (n = 6). *P < 0.050; **P < 0.010 
vs TnBs-treated rats.
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logical score (P = 0.010), and MPO activity (P < 0.001). 5-ASA 
treatment also restored normal histological appearance 
of the samples (Figure 2C). 1,25(OH)D3-treated rats also 
showed significantly decreased DAI value (P = 0.001), CDMI 
(P = 0.040), pathological score (P = 0.005), and MPO activity 
(P = 0.005). 1,25(OH)D3 treatment diminished the intensity of 
inflammatory infiltration in the lamina propria (Figure 2D).
Rats treated with both 5-ASA and 1,25(OH)D3 showed sig-
nificantly decreased MPO activity (P = 0.003), but the dif-
Figure 2. Microscopic features of colons. (A) Control group; (B) TnBs-treated group; (C) TnBs+ 5-asa treated group; (D) TnBs+ 
VitD3 treated group; (E) TnBs+5-asa+ VitD3 treated group. The sections were stained with hematoxylin and eosin. Magnification: 
200 × . TnBs, 2,4,6-trinitrobenzenesulfonic acid; 5-asa, 5-aminosalicylic acid; VitD3, 1,25-dihydroxyvitamin D.
Figure 3. serum calcium and creatinine profiles. (A) serum calcium levels (mmol/L). (B) serum creatinine levels (μmol/L). TnBs, 2,4,6-
trinitrobenzenesulfonic acid; 5-asa, 5-aminosalicylic acid; VitD3, 1,25-dihydroxyvitamin D. Data are presented as mean ± standard 
deviations (n = 6).
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ference in pathological score and MPO activity was not 
significant (P = 0.099) (Figure 1D-E). Thus, the combined 
treatment did not induce a synergistic effect.
rat blood serum calcium and creatinine profiles
To monitor the side effects of 1,25(OH)D3, hypercalcemia 
and renal insufficiency, we measured serum calcium lev-
els and serum creatinine levels. Treatment with 1,25(OH)D3 
alone and in combination with 5-ASA did not significantly 
alter serum calcium and creatinine levels (Figure 3).
5-asa and 1,25(OH)D3 down-regulate TLr9 expression 
and the number of TLr9 positive cells in TnBs-induced 
colitis
The mRNA expression of the TLR9 gene was determined 
using RT-PCR. TLR9 mRNA expression was significantly 
higher in the TNBS than in the control group (P = 0.008). In 
5-ASA-treated rats (P = 0.194) and 1,25(OH)D3-treated rats 
(P = 0.178) TLR9 gene expression was reduced compared 
to TNBS group, but neither reduction was statistically sig-
nificant (Figure 4A).
We then assessed the number of TLR9-positive cells by 
IHC. In the control group, only a few inflammatory TLR9-
positive cells were present in the epithelium, lamina, and 
submucosa. In TNBS-treated group, the number of TLR9-
positive cells was significantly higher (all P < 0.010) and 
they were mostly distributed in the lamina propria. Some 
goblet cells and epithelial cells were TLR9 positive (Figure 
5A-E). 5-ASA treatment, 1,25(OH)D3 treatment, and com-
bined treatment with 5-ASA and 1,25(OH)D3 significantly 
reduced the number of TLR9-positive inflammatory cells 
(P < 0.001, P = 0.008, P < 0.001, respectively) (Figure 4B). In 
TNBS-induced colitis group, a moderate correlation was 
detected between MPO activity and the number of TLR9-
positive cells (r = 0.654, P < 0.001) and a low non-significant 
correlation between MPO activity and TLR9 gene expres-
sion (r = 0.394, P = 0.057).
DisCussiOn
Consistent with the results of previous research (23,24), 
our study showed that 1,25(OH)D3 reduced inflamma-
tion in TNBS-induced colitis by suppressing infiltration of 
neutrophil granulocytes. However, the combined applica-
tion of 5-ASA and 1,25(OH)D3 was no more effective than 
treatment with 1,25(OH)D3 alone, suggesting no synergis-
tic effects. Vitamin D usage is considered as an adjuvant 
therapy in IBD, based on previous murine experiments and 
human studies (25,26). It is possible that the therapeutic 
effect of vitamin D is not substantial. Also the lack of syner-
gistic effects in our study might reflect an insufficient sta-
tistical power of our study. Though numerous studies have 
reported anti-inflammatory effect of 1,25(OH)D3 in vitro, 
Figure 4. expression of toll-like receptor 9 (TLr9) in colon. (A) relative expression of TLr9 mrna level in the colons from each group 
using β-actin as the internal control gene. (B) The number of TLr9 positive cells in colon from each group. (C) schematic diagram 
of TLr9 activation increases myeloperoxidase activity through nuclear factor kB signaling pathway. TLr, toll-like receptor; TnBs, 
2,4,6-trinitrobenzenesulfonic acid; 5-asa, 5-aminosalicylic acid; VitD3, 1,25-dihydroxyvitamin D; nF-kB, nuclear factor kB; TnF, tumor 
necrosis factor; iL, interleukin; iFn, interferon; MPO, myeloperoxidase; nVDr, nuclear vitamin D receptor. Data are presented as 
mean ± standard deviation (n = 6). **P < 0.010 vs TnBs-treated rats.
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only one placebo-controlled trial evaluated its effect in CD 
patients (27). Jorgensen et al (27) reported that treatment 
with vitamin D markedly reduced the rate of clinical relaps-
es from 29% to 13%, but the reduction was not significant. 
It is possible that 1,25(OH)D3 is beneficial to IBD patients, 
but further large-scale, multi-center clinical trials are need-
ed to investigate this issue.
TLRs are usually expressed in inflammatory cells, such as 
macrophages and dendritic cells, and play a central role 
in the innate immune system. TLR9 binds to unmethy-
lated CpG DNA in intestinal bacteria and activates an in-
testinal immune response through the NF-κB signaling 
pathway. We demonstrated that a small amount of TLR9 
was expressed in the colon of control rats, which is con-
sistent with previous studies (28,29). The limited expres-
sion of TLR9 in control rat colons could reduce intestinal 
commensal bacteria antigen recognition, and help control 
the specific immune response. In TNBS-induced colitis, a 
significant increase in TLR9 expression was observed. Con-
sistent with the results of previous studies in IBD patient 
specimens (30,31) and other animal experiments (32), our 
data showed that TLR9 was not only expressed in inflam-
matory cells in rats with colitis but also in epithelial cells 
and goblet cells. Lee et al (33) found that apical TLR9 stim-
ulation conferred tolerance to subsequent TLR challenge. 
Due to TLR9-assoiated activation, antigen-presenting cells 
produce IFN-α, resulting in activated Th1 cells, which pro-
duce pro-inflammatory cytokines, such as interleukin 6 and 
TNF-α. These pro-inflammatory cytokines activate neutro-
phil granulocytes, increasing the activity of MPO (34). The 
positive correlation between TLR9 expression and MPO ac-
tivity detected in our experiment is consistent with a pre-
vious study (35). Our data, along with these observations, 
suggested that TLR9 plays a crucial role in maintaining in-
testinal homeostasis.
Studies by Sadeghi et al and Dickie et al (36,37) both re-
ported that 1,25(OH)D3 suppressed the expression of TLR 
proteins and mRNA in human monocytes in a time- and 
dose-dependent fashion in vitro and reduced the recogni-
tion of bacterial specific antigens through monocytes. An-
other recent study showed that it decreased TLR-induced 
cytokine production and enhanced cytokine levels in pe-
ripheral mononuclear cells and monocyte-derived den-
dritic cells from CD patients (38). Our data showed that 
treating TNBS-induced colitis with 1,25(OH)D3 could 
reduce TLR9 expression in the rat colon. Moreover, 
Figure 5. immunohistochemical staining using an anti-TLr9 primary antibody. (A) Control group. (B) TnBs group. Cells that 
expressed TLr9 were mostly unevenly distributed in the lamina propria (red arrow). some goblet cells and epithelium cells were 
TLr9-positive (green arrow). (C) TnBs+5-asa group. (D) TnBs+ VitD3 group. (E) TnBs+5-asa+ VitD3 group. (F) negative control. 
Magnification: 400 × . TLr, toll-like receptor; TnBs, 2,4,6-trinitrobenzenesulfonic acid; 5-asa, 5-aminosalicylic acid; VitD3, 1,25-dihy-
droxyvitamin D.
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we demonstrated that the severity of colitis was correlated 
with TLR9 expression. Thus, we hypothesize that 1,25(OH)
D3 could relieve inflammation in TNBS-induced colitis by 
reducing TLR9 expression.
One of the study limitations is the small sample size, how-
ever the heterogeneity among rats was very low. We also 
did not use various concentration gradients of 1,25(OH)
D3. According to the United States Institute of Medicine, 
the recommended dietary allowance of vitamin D in adult 
people is 15 μg/d (39). Different doses of supplemental 
vitamin D are based on the 1,25(OH)D concentration. Pa-
tients suffering from osteoporosis are usually treated with 
calcitriol at a dose of 1 μg/d. Thus, we used 0.2 μg/kg/d 
1,25(OH)D3 to treat TNBS induced colitis, which is equiva-
lent to 1 μg/d in a human subject. Finally, we only used 
TNBS, instead of dextran sulfate sodium, to induce IBD 
in rats. Our choice was based on previous studies, which 
showed that the TNBS-induced acute colitis is a Th1-medi-
ated colitis, which resembles CD.
As vitamin D supplementation is readily available at a low 
cost, it is potentially a very attractive therapeutic option. 
The vitamin D analog, 22-ene-25-oxa-vitamin D (ZK156979) 
could both preserve immunosuppressive activity in vitro 
and ameliorate inflammation in TNBS-induced colitis with-
out causing hypercalcemia (40,41), which offers a new 
therapeutic option for the treatment of human IBD. In con-
clusion, our study showed that 1,25(OH)D3 relieved TNBS-
induced colitis in rats by down-regulating TLR-9, which 
might be associated with inflammation. Further studies 
are needed to clarify the exact molecular mechanisms in-
volved in this process.
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